Page last updated: 2024-10-22

ag-1296 and Brain Neoplasms

ag-1296 has been researched along with Brain Neoplasms in 1 studies

6,7-dimethoxy-3-phenylquinoxaline: ATP-competitive inhibitor of receptor kinase

Brain Neoplasms: Neoplasms of the intracranial components of the central nervous system, including the cerebral hemispheres, basal ganglia, hypothalamus, thalamus, brain stem, and cerebellum. Brain neoplasms are subdivided into primary (originating from brain tissue) and secondary (i.e., metastatic) forms. Primary neoplasms are subdivided into benign and malignant forms. In general, brain tumors may also be classified by age of onset, histologic type, or presenting location in the brain.

Research

Studies (1)

TimeframeStudies, this research(%)All Research%
pre-19900 (0.00)18.7374
1990's0 (0.00)18.2507
2000's0 (0.00)29.6817
2010's1 (100.00)24.3611
2020's0 (0.00)2.80

Authors

AuthorsStudies
Watanabe, T1
Ohtani, T1
Aihara, M1
Ishiuchi, S1

Other Studies

1 other study available for ag-1296 and Brain Neoplasms

ArticleYear
Enhanced antitumor effect of YM872 and AG1296 combination treatment on human glioblastoma xenograft models.
    Journal of neurosurgery, 2013, Volume: 118, Issue:4

    Topics: Animals; Antineoplastic Agents; Brain Neoplasms; Cell Line, Tumor; Cell Proliferation; Disease Model

2013